Pharming Group PHAR
Valuation
Multiples measured against the stock's own five-year history
Above its usual level · 77th percentile, 5-year average -1.6x
#2386 of 2991 stocks by PE (1 = cheapest)
Below its usual level · 38th percentile, 5-year average 3.4x
#3784 of 5328 stocks by PB (1 = cheapest)
Below its usual level · 27th percentile, 5-year average 2.9x
#2744 of 5155 stocks by PS (1 = cheapest)
P/E over five years
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Morningstar fair value estimate
| Multiple | Current | Forward | 5y average | Percentile vs. own history | Industry rank |
|---|---|---|---|---|---|
| PB | 3.06 | – | 3.37 | 38% (cheaper than usual) | #3784 of 5328 (1 = cheapest) |
| PE | 38.18 | 31.52 | -1.63 | 77% (pricier than usual) | #2386 of 2991 (1 = cheapest) |
| PS | 2.31 | 2.23 | 2.90 | 27% (cheaper than usual) | #2744 of 5155 (1 = cheapest) |
Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.
No comments yet — be the first to weigh in on PHAR.
Sign in to join the discussion.